Healthcare News

FY 2025/26 organic growth was 6% and EBIT growth1 in constant currencies was 4%. Reported revenue in DKK grew 4%, reflecting 2%-points negative impact from currencies. Organic growth rates by...

EINDHOVEN, the Netherlands, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement,...

The Novo Nordisk Foundation is awarding up to DKK 100 million (EUR 13.3 million) over four years to establish AI4GRIDS, a Nordic research initiative

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 03, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to...

Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 03. November 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...

Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO (aprocitentan).

November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the...

November 3, 2026Q3 2026 Group performance Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment Group sales of EUR 4.4 billion, reflecting 3% comparable sales...

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem...

Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...